Modification of mitogen-driven lymphoproliferation by ceftriaxone in normal and immunocompromised mice.
Cyclophosphamide-treated mice are proposed as a model to assay immunomodulation by antimicrobial agents in immunocompromised animals. Cyclophosphamide-treated BALB/c mice developed temporary leukopenia, myelopenia and spleen atrophy that was followed by splenomegaly. Cells from both atrophic and hypertrophic spleens exhibited impaired responses to mitogens and suppressed the mitogen-driven proliferation of normal splenocytes. This experimental model was applied to the study of immunomodulation by ceftriaxone. Ceftriaxone did not worsen the cyclophosphamide-damaged immunity mechanisms. On the contrary, cyclophosphamide-induced suppression of lymphoproliferation in response to concanavalin A was attenuated by ceftriaxone.
Jimenez-Valera
Maria
M
Department of Microbiology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain.
Moreno
Encarnacion
E
Amat
Maria Angeles
MA
Ruiz-Bravo
Alfonso
A
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D002443:Ceftriaxone / Q000494:pharmacology*; D003208:Concanavalin A / Q000494:pharmacology; D003520:Cyclophosphamide / Q000633:toxicity; D005260:Female; D016867:Immunocompromised Host / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000633:toxicity; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D008934:Mitogens / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D008934:Mitogens; D003208:Concanavalin A; D002443:Ceftriaxone; D003520:Cyclophosphamide